Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation (3AOD)

Centre Hospitalier Universitaire, Amiens

Status: Enrolling

Conditions: Adherence; Oral Anticoagulant

Treatments: Other: questionary

Study type: Interventional

Funder types: Other

Identifiers

NCT05469308

PI2022_843_0020

Details and patient eligibility

About

The rhythm disorders of Atrial Fibrillation (AF) require continuous treatment with anticoagulants to prevent stroke. The introduction of direct oral anticoagulants (DOACs) quickly supplanted the administration of anti-vitamin K (AVK) which presented an elevated risk of hemorrhage.

However, the adherence of the treatments by the OAD is very poor, several studies show that 30 to 50% of the patients fail to adhere to their treatment very soon after starting it. In a recent study, in the United States, using data collected between 2010 and 2014 in more than 60,000 patients with AF, Yao et al show that less than 50% of patients can be considered "adherent".

They conclude in this study that adherence to anticoagulation is low in practice, although it may be slightly improved with DOACs. More recently a meta-analysis shows that 66% of patient treated by DOACs were considered adherent (PDC > 80 %). In addition, therapeutic adherence seems to be essential in patients with a CHA2DS2-VASc score ≥2. Indeed improving adherence reduces the risk of stroke occurrence. The investigators propose to evaluate during an interview in the pharmacy, the adherence of ambulatory patients (at the time of their renewal of treatment at the pharmacy) by the "Proportion of Days Covered" (PDC) of the treatment by AOD, and by a simplified questionnaire and to define a profile of patients treated for AF at risk of nonadherence to AOD (PDC adherence prediction score). The investigators perform an observational, prospective multicenter study , in which patients adherence will be quantified in a standardized method.

Enrollment: 705 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Over the age of 18
• Consultation in the community pharmacy
• long-term treatment for at least six months with an DOACs.
• Patients able and agreeing to participate in the evaluation of their adherence

Exclusion criteria

• Treatment by DOACs limited in the duration
• Contra-indications of DOACs

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

705 participants in 1 patient group

questionary

Experimental group

Treatment:

Other: questionary